Shilpa Medicare Ltd. (SHILPAMED) Share Price Hits Fresh 52-Week High
- August 5, 2026
- Posted by: Harsh Piplani
- Category: News
Shilpa Medicare Ltd. Share Price hits a fresh 52-week high at Rs 666.35, rising 2.77% today. The market cap stands at Rs 12,190.61 crore.
Shilpa Medicare Ltd. Share Price reached a fresh 52-week high of Rs 666.35 today, marking a 2.77% increase from the previous close of Rs 648.4. The company’s market capitalisation is currently Rs 12,190.61 crore. This milestone highlights investor interest in the healthcare sector, where Shilpa Medicare operates. Despite the lack of a specific catalyst, the stock’s performance today underscores its relevance in the market.
Shilpa Medicare Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 666.35 |
| Previous Close | Rs 648.4 |
| Today's Change | +Rs 17.95 (+2.77%) |
| Day Open | Rs 650 |
| Fresh 52-Week High | Rs 666.35 |
| Day Low | Rs 636.85 |
| Current Volume | 49,230 |
| Turnover | Rs 3.28 crore |
| Market Capitalisation | Rs 12,190.61 crore |
Shilpa Medicare Ltd. (SHILPAMED) traded at Rs 666.35. versus the previous close of Rs 648.4, a rise of 2.77%. The stock opened at Rs 650, reached Rs 666.35, touched Rs 636.85. Reported volume was 49,230.
Today, Shilpa Medicare Ltd. opened at Rs 650 and reached a high of Rs 666.35, which is also its new 52-week high. The stock’s low for the day was Rs 636.85, and it closed with a turnover of Rs 3.28 crore. The current volume of 49,230 shares indicates active participation compared to average trading volumes. This price action suggests strong investor interest, setting the stage for further analysis of the company’s fundamentals.
Shilpa Medicare Ltd. (SHILPAMED) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 12,190.61 crore |
| P/E Ratio | 30.21x |
| P/B Ratio | 0.44x |
| ROE | -2.89% |
| ROCE | -0.26% |
Shilpa Medicare Ltd. was valued at a P/E ratio of 30.21x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 30.21x |
| Benchmark Median P/E | 21.71x |
| Benchmark Average P/E | 71.67x |
| Benchmark P/E Range | 0x to 3,385.56x |
| Company P/B Ratio | 0.44x |
| Benchmark Median P/B | 1.9x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.75% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.29% |
| Company Market Capitalisation | Rs 12,190.61 crore |
| Benchmark Median Market Cap | Rs 136.63 crore |
Shilpa Medicare Ltd. (SHILPAMED) is classified under sector: Healthcare.
Shilpa Medicare Ltd. (SHILPAMED) has a P/E ratio of 30.21x, which is above the benchmark median of 21.71x, a difference of +39.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Shilpa Medicare Ltd. (SHILPAMED) has a ROE of -2.89%, which is below the benchmark median of 10.75%, a difference of -126.88%. Shilpa Medicare Ltd. (SHILPAMED) has a ROCE of -0.26%, which is below the benchmark median of 13.29%, a difference of -101.96%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,945.17 | 30.21 | 0.44 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,652.68 | 39.86 | 8.11 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,608.51 | 63.2 | 10 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,457.9 | 32.25 | 6.65 | -2.6 | 16.92 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,451.51 | 164.6 | 3.04 | 13.9 | 12.97 |
Shilpa Medicare Ltd. (SHILPAMED) has a P/E ratio of 30.21x compared with the displayed peer median of 39.86x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Shilpa Medicare Ltd. (SHILPAMED) has a market capitalisation of Rs 12,190.61 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Shilpa Medicare Ltd.
- Achieved a fresh 52-week high at Rs 666.35.
- Active trading volume with a turnover of Rs 3.28 crore.
- Valuation above sector median P/E but challenges in profitability.
- Operates in a competitive healthcare sector with 198 peers.
About Shilpa Medicare Ltd.
Shilpa Medicare Ltd. is a prominent player in the healthcare sector, focusing on the development and manufacturing of pharmaceutical products. The company operates across various segments, including formulations and active pharmaceutical ingredients (APIs), catering to both domestic and international markets. With a strong emphasis on research and development, Shilpa Medicare aims to deliver innovative healthcare solutions. Despite facing profitability challenges, the company remains a key participant in the competitive pharmaceutical landscape.
Track Shilpa Medicare Ltd. Share Price on Univest
Use Shilpa Medicare Ltd. (SHILPAMED) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Shilpa Medicare Ltd. Share Price, technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest. Stay informed with real-time data and comprehensive analysis to make well-informed investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Shilpa Medicare Ltd.?
Ans. The current share price of Shilpa Medicare Ltd. is Rs 666.35, marking a fresh 52-week high with a 2.77% increase from the previous close. The stock moved 2.77% during the session.
What is Shilpa Medicare Ltd.'s market capitalisation?
Ans. Shilpa Medicare Ltd.'s market capitalisation is Rs 12,190.61 crore, positioning it as a significant player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.21x.
How does Shilpa Medicare Ltd.'s P/E ratio compare to the sector?
Ans. Shilpa Medicare Ltd.'s P/E ratio of 30.21 is above the sector median of 21.71, indicating a relatively higher valuation. The company trades at a P/E ratio of 30.21x. Its P/B ratio is 0.44x.
What are the profitability metrics for Shilpa Medicare Ltd.?
Ans. Shilpa Medicare Ltd. has a negative ROE of -2.89% and ROCE of -0.26%, highlighting challenges in profitability and capital efficiency. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.75%.
Who are Shilpa Medicare Ltd.'s main competitors?
Ans. Main competitors include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., and Beta Drugs Ltd., among others in the healthcare sector. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd.
What is the P/B ratio of Shilpa Medicare Ltd.?
Ans. Shilpa Medicare Ltd.'s P/B ratio is 0.44, significantly lower than the sector median of 1.9, suggesting a potentially undervalued position. The company trades at a P/E ratio of 30.21x. Its P/B ratio is 0.44x.
How does Shilpa Medicare Ltd. compare to its peers?
Ans. Shilpa Medicare Ltd. has a similar P/E ratio to peers but lags in profitability metrics like ROE and ROCE compared to companies like Kwality Pharmaceuticals Ltd. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd.
